Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted... | March 28, 2023

Related Keywords

Lincoln Park ,Illinois ,United States ,Chicago ,Jim Fickenscher ,Armando Anido ,Peter Vozzo ,Vp Corporate Development ,Ladenburg Thalmann Co ,Canaccord Genuity ,Trademark Office ,Silicon Valley Bank ,Lincoln Park Capital Fund ,Zynerba Pharmaceuticals ,European Medicines Agency ,Nasdaq ,Exchange Commission ,Meeting Of The American College Neuropsychopharmacology ,Zynerba Pharmaceuticals Inc ,European Commission ,Hc Wainwright Co ,Cantor Fitzgerald Co ,Drug Administration ,Chief Executive Officer ,Fragilex Syndrome ,New Drug Application ,Marketing Authorization Application ,Neurodevelopmental Disorders ,Press Release ,Fragilex Syndrome With Cannabidiol ,Annual Meeting ,American College ,Pediatric Anxiety Rating Scale ,Mood Scale ,Aberrant Behavior Checklist ,Syndrome With Cannabidiol ,Full Year ,Silicon Valley ,Controlled Equity ,Cantor Fitzgerald ,Ladenburg Thalmann ,Purchase Agreement ,Fast Track ,Private Securities Litigation Reform Act ,Nc Stock Exchange ,News ,Information ,Enrollment ,Ontinues ,N ,Confirmatory ,Pivotal ,Hase , ,Trial ,F ,Patients ,Ith ,Fragile ,Topline ,Results ,Xpected ,024 ,European ,Ommission Zyne Us98986x1090 ,